Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: Methodology of clinical trials and clinical benefit

•Metastatic renal cell carcinoma is an incurable cancer.•Gain in progression-free survival with new drugs is around 3months.•Patient-reported outcomes are an essential endpoint with strong impact on clinical benefit.•The quality of the methodology and the data analysis of patient-reported outcomes are not yet optimal.•New-generation therapies should demonstrate not only a gain in survival but also in quality of life.